Company patents
Albireo AB
Albireo AB's patent strategy is heavily concentrated in pharma_biotech, with its largest category, Therapeutic Activity (71.7% of portfolio), showing a significant 42.9% growth in 2025 before a sharp decline so far in 2026. While the company maintains a strong focus on core areas like Pharmaceutical Preparations and Heterocyclic Compounds (both 56.5% of portfolio), the complete cessation of patenting in Material & Chemical Analysis since 2023 and a 100% decline in Peptides & Proteins in 2024 suggest a clear shift away from these areas.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
46 US filings (since 2023) · 6 categories · 5 themes
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Techniques for preparing and characterizing specific solid forms, such as crystal forms, salts, co-crystals, or amorphous forms, of active pharmaceutical ingredients to optimize properties like stability, solubility, and bioavailability.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Development and use of engineered biological systems, such as organ-on-a-chip devices, dynamic hydrogels, or genetically modified cells, to mimic physiological conditions, study disease mechanisms, screen compounds, or develop cell-based therapies.
Patents
Showing 1-3 of 3
API Solid Form Engineering